Loading...
XSHG
603456
Market cap1.81bUSD
Jul 09, Last price  
13.95CNY
1D
-1.13%
1Q
-19.55%
Jan 2017
16.44%
IPO
105.45%
Name

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603456 chart
P/E
16.85
P/S
2.23
EPS
0.83
Div Yield, %
3.58%
Shrs. gr., 5y
2.08%
Rev. gr., 5y
15.78%
Revenues
5.51b
+6.74%
590,669,767652,528,857833,378,939935,110,2281,143,419,7501,309,584,2041,286,206,7651,444,511,0841,653,177,2091,717,440,5991,862,225,1582,016,815,8532,647,284,1624,063,181,9155,445,105,1545,523,418,1745,160,584,7255,508,595,171
Net income
730m
+20.46%
41,423,75267,211,243109,859,779117,049,728136,256,788166,240,816133,278,527200,079,305111,480,464147,605,267157,147,459237,793,383380,584,954633,900,948921,170,3751,033,255,691606,096,358730,073,370
CFO
1.82b
+83.96%
82,841,684122,025,843105,299,432111,006,749154,281,690203,861,15310,167,664140,525,669136,646,433244,201,283264,782,500554,161,971400,392,398677,519,2361,225,782,0921,360,323,930991,655,1741,824,246,221
Dividend
Sep 08, 20250.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, a company established in 1973 and operating from its headquarters in Taizhou, China, specializes in the production and global supply of active pharmaceutical ingredients (APIs) and their chemical precursors. Its extensive product catalog includes APIs designed for a wide range of therapeutic applications, encompassing treatments for central nervous system disorders (such as anti-depressants and Parkinson's disease), various infectious ailments (including antiviral, general anti-infection, and specific respiratory anti-infection agents), diabetes management, non-steroidal drugs, oncological therapies, Hepatitis C, and cardiovascular conditions. Furthermore, beyond its pharmaceutical focus, the company also furnishes specialized asymmetric catalysts and crucial materials utilized in lithium-ion batteries.
IPO date
Oct 10, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT